Two years ago when Biotime announced their cancer detection program we shot up to $10. From what i know, we have patented DNA bio-markers that are better than anything on the market today, the test will be inexpensive and done from a blood sample. No more mammograms!
Looking forward to OncoCyte's update, should pop us back to $10 level if that's the case.
Cancer diagnostics update soon. Biotime working hard to add additional gene markers into the mix after Supreme court ruling. Gonna be big!!
intelliCell needs to:
A) Correct some lab requirements to appease the FDA
B) Selling out to a large pharma
C)Merge with a cutting edge company who needs a device for adipose reconstructive surgery(like BTX)
Cramer from 'Mad Money' will be hitting the 'BUY-BUY-BUY!' button when PanC is officially announced.
Mid May Biotime will be at Gene Convention, LifeMaps fast becoming a hub for genetic research. Hats off to Dr. West's foresight.
The 5 yr chart is roughly the time frame from when Dr. West took over as CEO.
0.30 to $4 with a $10 high.
$10 high was a couple of years back when BTX announced their cutting edge cancer detection IP. Later this year we should have an update/partnership, and most likely shoot us back up to $10 range.
Appistry is an exclusive provider of GATK, the most flexible toolkit for genomics analysis.
My hope is that BTX eventually absorbs them up, like they did with LifeMap.
Information these day is KING, very happy West is moving in this direction, very smart!
Ok, NOW i am convinced that BTX is past the point of being a 'high-risk' stock. I now believe acquiring LifeMaps was key, and with todays news Biotime is on it's way at being totally self sufficient.
More on Appistry Inc:
Appistry Inc. provides analytics and data management solutions to corporations, Fortune 100 companies, and government agencies worldwide. It offers Ayrris, an open, scalable solution for data-intensive applications. The company also provides AYRRIS/BIONGS Analytics that employs analytical pipelines designed to automate the analysis and management of specific types of data; and AYRRIS/BIOData Management, which provides data management solutions adapted to support NGS Analytics for the life sciences sector. In addition, it offers Ayrris/DEFENSE that offers high-volume data ingest, storage, analysis, and delivery for the intelligence and defense organizations; and Ayrris/FINANCE delivers high-speed data ingest, storage, analysis, and delivery for the financial services industry. The company offers its solution via self-hosted hardware deployment or through its remotely hosted pay-per-use service. Appistry Inc. was formerly known as Tsunami Research, Inc. and changed its name to Appistry Inc. in April 2005. The company was founded in 2001 and is headquartered in St. Louis, Missouri.
Biotime research product revenues next month should be a major step in our ability to pay for our clinical trials.
Cornell has an incentive to help out with the trials and get things going because BTX is licensing a patent form them. Cornell will get a cut from Biotimes vascular therapeutics profits, so it's all good.
Great post, and you didn't even mention Biotimes research product lines that will be of great importance as the medical world changes over to the regenerative technology.
Biotimes hydrogels already have approval, Renevia is based on their extra-cellular matrix IP, CE mark in EU will get things rolling in a short while....hang in there!